MedTrace Logo

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

NCT03050099 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 560

Last updated 2017-03-03

No results posted yet for this study

Summary

A multi-protein test using mass spectrometry (MS) for multiplexed protein quantitation is being developed. This test and the accompanying decision-aid software will provide Transient Ischemic Attack (TIA) results rapidly for a fraction of the price of neuroimaging. With guidance provided by this test, Emergency Department (ED) physicians can manage medical imaging questions such as the use of Computed Tomography Angiography (CTA) prior to ED discharge and appropriate (timely) referral to stroke clinics for consultation and follow-up care. The right patients will receive the right treatment, reduce unwarranted imaging risks and costs, and reduce the burden of stroke.

Conditions

  • TIA

Interventions

OTHER

Non-Interventional Study

This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.

Sponsors & Collaborators

  • Genome Canada

    collaborator OTHER

  • Genome British Columbia

    collaborator INDUSTRY

  • Genome Alberta

    collaborator OTHER

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • Stroke Services BC

    collaborator UNKNOWN

  • Bruker Daltonics

    collaborator INDUSTRY

  • LifeLabs

    collaborator UNKNOWN

  • Andrew Penn

    lead OTHER

Principal Investigators

  • Andrew M Penn, M.D · Vancouver Island Health Authority

  • Shelagh Coutts, M.D. · Alberta Health services

  • Christoph Borchers, P.hD · UVic- Genome BC Proteomics Centre

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-01
Primary Completion
2015-06-30
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03050099 on ClinicalTrials.gov